CN113615836A - Cathay hickory oil composition with function of reducing blood pressure and preparation method thereof - Google Patents
Cathay hickory oil composition with function of reducing blood pressure and preparation method thereof Download PDFInfo
- Publication number
- CN113615836A CN113615836A CN202110705572.XA CN202110705572A CN113615836A CN 113615836 A CN113615836 A CN 113615836A CN 202110705572 A CN202110705572 A CN 202110705572A CN 113615836 A CN113615836 A CN 113615836A
- Authority
- CN
- China
- Prior art keywords
- blood pressure
- oil composition
- function
- reducing blood
- pecan oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 230000036772 blood pressure Effects 0.000 title claims abstract description 46
- 230000001603 reducing effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 240000004875 Carya cathayensis Species 0.000 title description 4
- 235000005663 Carya cathayensis Nutrition 0.000 title description 4
- 235000019495 Pecan oil Nutrition 0.000 claims abstract description 51
- 239000010470 pecan oil Substances 0.000 claims abstract description 51
- 239000000284 extract Substances 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 8
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 8
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 7
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 7
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 6
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 6
- 244000194101 Ginkgo biloba Species 0.000 claims abstract 3
- 239000003921 oil Substances 0.000 claims description 24
- 235000019198 oils Nutrition 0.000 claims description 24
- 241000723418 Carya Species 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- -1 sucrose fatty acid ester Chemical class 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000003825 pressing Methods 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 238000010025 steaming Methods 0.000 claims description 5
- 238000007670 refining Methods 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 235000017709 saponins Nutrition 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 239000009277 Panax notoginseng extract Substances 0.000 claims description 2
- 150000002596 lactones Chemical class 0.000 claims description 2
- 241000208689 Eucommia ulmoides Species 0.000 claims 2
- 239000009429 Ginkgo biloba extract Substances 0.000 claims 1
- 235000019498 Walnut oil Nutrition 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 229940068052 ginkgo biloba extract Drugs 0.000 claims 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims 1
- 239000008170 walnut oil Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 229940126673 western medicines Drugs 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 2
- 239000002220 antihypertensive agent Substances 0.000 abstract description 2
- 229940127088 antihypertensive drug Drugs 0.000 abstract description 2
- 235000019658 bitter taste Nutrition 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 241000208688 Eucommia Species 0.000 abstract 1
- 244000269722 Thea sinensis Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 43
- 230000000052 comparative effect Effects 0.000 description 29
- 230000006870 function Effects 0.000 description 20
- 230000035488 systolic blood pressure Effects 0.000 description 19
- 230000035487 diastolic blood pressure Effects 0.000 description 16
- 239000010495 camellia oil Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 244000237330 gutta percha tree Species 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 241000218628 Ginkgo Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 4
- 241001122767 Theaceae Species 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 229930183798 Camelliaside Natural products 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of functional health food preparation, and particularly relates to a pecan oil composition with a function of reducing blood pressure and a preparation method thereof. The health-care tea uses the pecan oil, the eucommia bark extract, the ginkgo extract, the pseudo-ginseng extract and the soybean lecithin as main raw materials, has the function of reducing blood pressure by utilizing the comprehensive action of various components, and is non-toxic and harmless to human bodies. The invention has rich nutrition, no bitter taste and convenient taking, and conforms to the regulations of the national food sanitation law. The pecan oil composition can be used independently by patients with mild symptoms, can be used together with other antihypertensive drugs for treating severe diseases, can greatly reduce the use amount of common antihypertensive western medicines, has obvious treatment effect, and can remarkably slow down or eliminate other complications.
Description
Technical Field
The invention belongs to the technical field of functional health food preparation, and particularly relates to a pecan oil composition with a function of reducing blood pressure and a preparation method thereof.
Background
Hypertension is the most important risk factor for cardiovascular diseases, often causes complications of heart, brain, kidney and other organs, and seriously harms human health. In 2010, the number of hypertension patients in China has exceeded 2 billion, and continues to increase at 1 million per year. Moreover, hypertension is no longer a 'patent' for the middle-aged and elderly, and the prevalence rate of hypertension in people under 30 years old has reached 10%, with the rising trend being far higher than that of the elderly. Cardiovascular diseases become the first cause of death for residents in China, and statistics show that 50% of 300 million cardiovascular patients who die every year in China are related to hypertension. Therefore, the understanding of hypertension is improved, and the Chinese medicinal composition has extremely important significance for early prevention and timely treatment.
The modern medicine for treating hypertension generally comprises the following steps: dietotherapy, tea therapy, health care, traditional Chinese medicine and finally western medicines. In order to control blood pressure, various methods other than taking medicines have been proposed. In dietetic china, it is common practice to prevent or ameliorate certain diseases through the use of food intake. The pecan oil is extracted from fruits of wild woody plants of the oil family, and is one of four woody plant oils in the world. The dual functions of food therapy of Chinese hickory oil are actually superior to olive oil, and besides the fatty acid compositions, the grease characteristics and the nutritional ingredients of the two types of grease are similar, the tea oil also contains tea polyphenol and camelliaside (tea saponin, or called tea saponin) which are specific physiological active substances and are not contained in the olive oil. The content of monounsaturated fatty acid exceeds that of olive oil and reaches 80 percent; tea oil is rich in vitamin E, twice as high as olive oil. Tea oil is collected and carried as medicinal oil in the Chinese pharmacopoeia (1995 edition), and has good effect for oral administration and external application because the tea oil is rich in various nutritional ingredients. It can be taken frequently to inhibit aging, and has good effects in preventing chronic pharyngitis and hypertension, arteriosclerosis, and cardiovascular system diseases.
The phytosterol is a natural active substance which can effectively reduce cholesterol, can inhibit the absorption of human body to cholesterol, and has the functions of reducing cholesterol and preventing cardiovascular diseases. The human body can not synthesize the phytosterol and must obtain the phytosterol from the diet, and the edible oil is an important channel for people to take the phytosterol from the diet. Since the pecan oil has low content of phytosterol and has no obvious effect on reducing cholesterol, Chinese patent application (CN101869152A) discloses a preparation method of refined health-care pecan oil with the phytosterol and the pecan oil compatible, although the method can lead the total content of the sterol in the pecan oil to be 10000-15000 mg/L. However, the health care product prepared by adopting the single pecan oil does not have obvious effect of reducing the blood pressure, so that the composition which takes the pecan oil as the main component and has better function of reducing the blood pressure is necessary.
Disclosure of Invention
The invention aims to solve the problems in the prior art and provides a pecan oil composition which takes natural botanical drugs as raw materials and has the function of reducing blood pressure and a simple preparation method.
The purpose of the invention can be realized by the following technical scheme:
the pecan oil composition with the function of reducing blood pressure comprises the following raw materials in parts by weight: 50-95 parts of hickory oil, 1-10 parts of eucommia ulmoides extract, 2-20 parts of ginkgo extract, 1-10 parts of pseudo-ginseng extract, 2-8 parts of soybean lecithin and 0.5-3 parts of auxiliary material.
In the pecan oil composition with the function of reducing blood pressure, the auxiliary materials are mixed according to a mass ratio of 1: (0.5-2) sucrose fatty acid ester and vitamin E mixture.
The invention develops a pecan oil composition with the function of reducing blood pressure by taking natural plant medicines as raw materials and simple preparation method based on the functions of preventing cardiovascular diseases and improving myocardial functions of pecan oil and matching with various functions of tonifying liver and kidney, strengthening bones and muscles, reducing blood pressure and the like of eucommia ulmoides, wherein the adopted eucommia ulmoides extract is obtained by chemically extracting dried bark of eucommia ulmoides in the family of eucommia ulmoides, and the ginkgo extract is used for assisting in treating symptoms such as coronary heart disease, angina pectoris, chest distress, shortness of breath and the like, and the pseudo-ginseng extract has obvious blood fat regulating effect and immunoregulation effect, has obvious compound synergism and has good blood pressure reducing effect.
In the pecan oil composition with the function of reducing blood pressure, the pecan oil contains phytosterol with the content of not less than 10000mg/L and unsaturated fatty acid with the content of not less than 80%.
In the pecan oil composition with the function of reducing blood pressure, the total flavone of the ginkgo extract is not less than 15 percent, and the lactone is not less than 3 percent.
In the pecan oil composition with the function of reducing blood pressure, the total saponins of the panax notoginseng extract accounts for 10-80 percent.
The invention also provides a preparation method of the pecan oil composition with the function of reducing blood pressure, which comprises the following steps:
s1, drying the hickory oil seeds, removing shells, crushing, moistening, steaming, frying, squeezing to obtain a crude hickory oil product, refining to obtain edible hickory oil, and adding phytosterol to obtain the hickory oil;
s2, preparing raw materials;
s3, homogenizing and mixing the hickory oil, the eucommia ulmoides extract, the ginkgo extract, the pseudo-ginseng extract, the soybean lecithin and auxiliary materials to obtain a thick mixture;
s4, pressing the thick mixture to obtain the pecan oil composition.
Preferably, in step S1, fresh pecan oil seeds are dried, the pecan oil seeds are shelled, then the pecan oil seeds are processed into powder by a pulverizer, the powder is wet by steam or water spray and then is subjected to wet steaming and frying, a tea oil crude product is obtained by squeezing by a screw press, then the tea oil crude product is subjected to a refining process to obtain edible tea oil, and the tea oil is added with phytosterol until the sterol content in the tea oil is detected to be higher than 10000mg/L, so that the pecan oil is obtained.
Preferably, the refining step includes deacidification, washing with water, and purification of a smell.
In the preparation method of the pecan oil composition with the function of reducing blood pressure, the water content of the dried pecan oil seeds in the step S1 is 5-6%.
In the preparation method of the pecan oil composition with the function of reducing blood pressure, the steaming and frying temperature of the step S1 is 130-.
In the preparation method of the pecan oil composition with the function of reducing blood pressure, the temperature of the homogenized material in the step S3 is 30-70 ℃, and the pressure is 15-25 Mpa. The invention carries out homogeneous mixing at 30-70 ℃, is beneficial to mixing all the components, has not very high temperature and can also ensure the chemical stability of all the components. Under 15-25MPa, the raw material is easy to be homogenized quickly, so that all components of the raw material are formed into a uniform and single-phase mixture from a dispersed and non-uniform multi-phase mixture, and the average particle size of the raw material is reduced after the raw material is homogenized under high pressure, so that the stability, the absorptivity and the functionality of the raw material are greatly improved.
In the above preparation method of the pecan oil composition having the function of lowering blood pressure, the pecan oil composition prepared by the pressing method of step S4 is a capsule.
Preferably, the method for preparing the capsule by the compression method comprises the following steps:
firstly, according to the formula of a capsule wall material, putting gelatin into distilled water for soaking to swell, adding other materials together after the gelatin is dissolved, and stirring and mixing uniformly;
secondly, taking out the prepared capsule wall glue solution, coating the capsule wall glue solution on the surface of a flat plate to ensure that the thickness is uniform, and then heating the capsule wall glue solution at the temperature of about 90 ℃ to evaporate the water on the surface to form a soft film with certain toughness and certain elasticity;
thirdly, pressing the soft capsules; when in small-batch production, the mixture is manually pressed by a pill pressing die; in mass production, an automatic rotary bag rolling machine is often adopted for production.
Compared with the prior art, the invention has the following beneficial effects:
1. the invention selects natural plant medicines as raw materials, utilizes the comprehensive effect of various components to ensure that the traditional Chinese medicine composition has the function of reducing blood pressure and is non-toxic and harmless to human bodies.
2. The invention has rich nutrition, no bitter taste and convenient taking, and conforms to the regulations of the national food sanitation law.
3. The pecan oil composition can be used independently by patients with mild symptoms, can be used together with other antihypertensive drugs for treating severe diseases, can greatly reduce the use amount of common antihypertensive western medicines, has obvious treatment effect, and can remarkably slow down or eliminate other complications.
Detailed Description
The following are specific examples of the present invention and further describe the technical solutions of the present invention, but the present invention is not limited to these examples.
Examples 1 to 4:
s1, drying fresh pecan oil seeds, controlling the water content to be 5-6%, shelling, crushing, moistening, steaming and frying at 135 ℃, controlling the water content to be 3-4%, squeezing to obtain a pecan oil crude product, deacidifying, washing with water, and deodorizing to obtain edible pecan oil, detecting the content of unsaturated fatty acids in the tea oil to be not less than 80%, and the content of sterols to be not less than 1000mg/L, adding phytosterol, and stirring uniformly until the content of sterols in the tea oil to be higher than 10000mg/L to obtain the pecan oil;
s2, preparing raw materials according to the table 1;
s3, homogenizing and mixing hickory oil, eucommia ulmoides extracts, ginkgo extracts, pseudo-ginseng extracts, soybean lecithin and auxiliary materials at 50 ℃ and 20MPa to obtain a thick mixture;
s4, pressing the thick mixture to obtain the pecan oil composition.
Application example 1:
10 male SHR rats of 10 weeks old were bred for 20 days, and then the blood pressure basic value and body weight were measured to prepare the compound hickory oil of example 1 at a dose of 0.5 g/kg-1The low dose was administered continuously for 4 weeks, and at 1, 2, 3, 4 weeks, each group of rats was weighed and then measured for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Blood Pressure (MBP), and Heart Rate (HR).
Application example 2:
10 male SHR rats of 10 weeks old were bred for 20 days, and the blood pressure and body weight were measured to obtain compound hickory oil of example 1 at a dose of 1.0 g/kg-1The medium dose was administered continuously for 4 weeks. At 1, 2, 3, 4 weeks of administration, each group of rats was weighed and then measured for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Blood Pressure (MBP) and Heart Rate (HR).
Application example 3:
10 male SHR rats of 10 weeks old were bred for 20 days, and the blood pressure and body weight were measured to obtain compound hickory oil of example 1 at a dose of 2.0 g/kg-1High doses were administered continuously for 4 weeks. At 1, 2, 3, 4 weeks of administration, each group of rats was weighed and then measured for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Blood Pressure (MBP) and Heart Rate (HR).
Application comparative example 1:
the preparation method of the 2 percent sucrose fatty ester solution comprises the following steps: 20g of sucrose fatty acid ester (Mitsubishi corporation, 0Z10940A) was added to 1000ml of 98 ℃ distilled water, and the mixture was stirred and homogenized by a homogenizer, cooled, and stored at 4 ℃.
10 male SHR rats of 10 weeks old were bred for 20 days, and then a 2% sucrose fatty ester solution (10 mL. kg.) was prepared by measuring the blood pressure basal value and body weight-1) Administration was continued for 4 weeks. At 1, 2, 3, 4 weeks of administration, each group of rats was weighed and then measured for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Blood Pressure (MBP) and Heart Rate (HR).
Application comparative example 2:
the preparation method of the 2 percent sucrose fatty ester solution comprises the following steps: 20g of sucrose fatty acid ester (Mitsubishi corporation, 0Z10940A) was added to 1000ml of 98 ℃ distilled water, and the mixture was stirred and homogenized by a homogenizer, cooled, and stored at 4 ℃.
10 male Wistar rats aged 10 weeks were bred for 20 days, and then the blood pressure basal value and body weight were measured to prepare a 2% sucrose fatty ester solution (10 mL. kg.)-1) Administration was continued for 4 weeks. At 1, 2, 3, 4 weeks of administration, each group of rats was weighed and then measured for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Blood Pressure (MBP) and Heart Rate (HR).
Data processing: statistical analysis was performed using SPSS13.0 software, with the remaining data being averaged. + -. standard deviation
The test results are shown, evaluated by the application of t-test to the metrology data.
Table 1: EXAMPLES 1-4 blending ratio of raw materials of Carya cathayensis oil composition
Table 2: using examples 1-3, using comparative examples 1-2 rats varied in body weight over different dosing periods (g, n-10,
)
table 3: using examples 1-3, using comparative examples 1-2 rats the Systolic Blood Pressure (SBP) was varied at different dosing periods (mmHg, n-10,
)
table 4: using examples 1-3, using comparative examples 1-2, the variation of diastolic pressure (DBP) in rats at different dosing stages (mmHg, n-10,
)
table 5: use examples 1-3, use comparative examples 1-2 averaging of rats at different dosing stagesVariation in pressure (MBP) (mmHg, n10,
)
table 6: using example 1, using comparative examples 1-2 rats varied in Heart Rate (HR) over different dosing periods (bpm, n-10,
)
as can be seen from table 2, the weight before administration of SHR rats of the application comparative example 1 was significantly higher than that of the application comparative example 2, and the weight of the rats of the application comparative example 1 was significantly lower than that of the rats of the application comparative example 2 from the beginning of 3 weeks of administration; compared with application comparative example 1, 0.5, 1.0, 2.0 g.kg were given-1After 4 weeks, the weight average of rats in the administration group was not significantly changed in the rats of examples 1 to 3.
As can be seen from Table 3, compared with the application comparative example 2, the SHR rat using the application comparative example 1 has significantly higher systolic pressure before and after administration than the rat using the application comparative example 2; compared with application comparative example 1, 0.5, 1.0, 2.0 g.kg were given-14 weeks later, high dose group (2.0 g.kg) of rats treated with compound hickory oil-1) The systolic pressure of rats is remarkably reduced at 2, 3 and 4 weeks of administration, and the medium dose group (1.0 g.kg)-1) The rats showed significant reduction in systolic blood pressure at 2 and 4 weeks of administration, and the low dose group (0.5 g.kg)-1) The systolic blood pressure was significantly reduced in rats at 2 weeks of administration.
As can be seen from Table 4, in comparison with comparative example 2, which is applied, it should be noted thatThe post-and pre-administration diastolic pressures of the SHR rats of comparative example 1 were significantly higher than the systolic pressure of the SHR rats of comparative example 2; compared with application comparative example 1, 0.5, 1.0, 2.0 g.kg were given-14 weeks later, high dose group (2.0 g.kg) of rats treated with compound hickory oil-1) The diastolic pressure of rats was significantly reduced at 2, 3 and 4 weeks after administration, and the medium dose group (1.0 g. kg)-1) The diastolic pressure of the rats is obviously reduced at 2 and 4 weeks of administration, and the low dose group (0.5 g.kg)-1) The diastolic pressure was significantly reduced in rats at 2 weeks of administration.
As can be seen from Table 5, compared with the use of comparative example 2, the average pressure before and after administration of the SHR rat using comparative example 1 was significantly higher than the systolic pressure of the rat using comparative example 2; compared with application comparative example 1, 0.5, 1.0, 2.0 g.kg were given-14 weeks later, high dose group (2.0 g.kg) of rats treated with compound hickory oil-1) The average pressure of rats is remarkably reduced at 2, 3 and 4 weeks of administration, and the medium dose group (1.0 g.kg)-1) The average pressure of rats is obviously reduced at 2 and 4 weeks of administration, and the low dose group (0.5 g.kg)-1) The mean pressure in rats was significantly reduced at 2 weeks of administration.
As can be seen from Table 6, compared with the application comparative example 2, the heart rate before and after administration of the SHR rat using the application comparative example 1 is significantly higher than the systolic pressure of the rat using the application comparative example 2; compared with application comparative example 1, 0.5, 1.0, 2.0 g.kg were given-1After 4 weeks, the heart rate times of rats of each administration group have no obvious change.
The above results preliminarily show that the blood pressure of the SHR rats using comparative example 1 is significantly higher than that of the normal Wistar rats and increases with the increase of the week age; the compound hickory oil can obviously inhibit the increase of the blood pressure of SHR rats, and the action way of the compound hickory oil is probably to inhibit the increase of the blood pressure by softening blood vessels. The compound hickory oil of the invention can inhibit the blood pressure rise of SHR rats.
The technical scope of the invention claimed by the embodiments of the present application is not exhaustive, and new technical solutions formed by equivalent replacement of single or multiple technical features in the technical solutions of the embodiments are also within the scope of the invention claimed by the present application; in all the embodiments of the present invention, which are listed or not listed, each parameter in the same embodiment only represents an example (i.e., a feasible embodiment) of the technical solution, and there is no strict matching and limiting relationship between the parameters, wherein the parameters may be replaced with each other without departing from the axiom and the requirements of the present invention, unless otherwise specified. The technical means disclosed by the scheme of the invention are not limited to the technical means disclosed by the technical means, and the technical scheme also comprises the technical scheme formed by any combination of the technical characteristics. While the foregoing is directed to embodiments of the present invention, it will be appreciated by those skilled in the art that various changes may be made in the embodiments without departing from the principles of the invention, and that such changes and modifications are intended to be included within the scope of the invention.
The specific embodiments described herein are merely illustrative of the spirit of the invention. Various modifications or additions may be made to the described embodiments or alternatives may be employed by those skilled in the art without departing from the spirit or ambit of the invention as defined in the appended claims.
Claims (10)
1. The pecan oil composition with the function of reducing blood pressure is characterized by comprising the following raw materials in parts by weight: 50-95 parts of hickory oil, 1-10 parts of eucommia ulmoides extract, 2-20 parts of ginkgo extract, 1-10 parts of pseudo-ginseng extract, 2-8 parts of soybean lecithin and 0.5-3 parts of auxiliary material.
2. The pecan oil composition with the function of reducing blood pressure as claimed in claim 1, wherein the auxiliary materials comprise, by mass, 1: (0.5-2) sucrose fatty acid ester and vitamin E mixture.
3. The pecan oil composition having the function of lowering blood pressure as claimed in claim 1, wherein the pecan oil contains phytosterol in an amount of not less than 10000mg/L and unsaturated fatty acid in an amount of not less than 80%.
4. The pecan oil composition with the function of reducing blood pressure as claimed in claim 1, wherein the ginkgo biloba extract total flavonoids is not less than 15% and the lactones are not less than 3%.
5. The pecan oil composition with the function of reducing blood pressure as claimed in claim 1, wherein the total saponins of panax notoginseng extract is 10-80%.
6. A method for preparing the pecan oil composition with the function of reducing blood pressure according to claim 1, which comprises the following steps:
s1, drying the hickory oil seeds, removing shells, crushing, moistening, steaming, frying, squeezing to obtain a crude hickory oil product, refining to obtain edible hickory oil, and adding phytosterol to obtain the hickory oil;
s2, preparing raw materials;
s3, homogenizing and mixing the hickory oil, the eucommia ulmoides extract, the ginkgo extract, the pseudo-ginseng extract, the soybean lecithin and auxiliary materials to obtain a thick mixture;
s4, pressing the thick mixture to obtain the pecan oil composition.
7. The method for preparing the pecan oil composition with the function of reducing blood pressure as claimed in claim 6, wherein the water content of the pecan oil seeds dried in the step S1 is 5% -6%.
8. The method as claimed in claim 6, wherein the temperature of the step S1 is 130-140 ℃, and the water content of the walnut oil seeds after the step S1 is 3-4%.
9. The method for preparing the pecan oil composition with the function of reducing blood pressure according to claim 6, wherein the temperature of the homogenized material in the step S3 is 30-70 ℃, and the pressure is 15-25 MPa.
10. The method for preparing the pecan oil composition with the function of reducing blood pressure as claimed in claim 6, wherein the pecan oil composition prepared by the pressing method of step S4 is in the form of capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110705572.XA CN113615836A (en) | 2021-06-24 | 2021-06-24 | Cathay hickory oil composition with function of reducing blood pressure and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110705572.XA CN113615836A (en) | 2021-06-24 | 2021-06-24 | Cathay hickory oil composition with function of reducing blood pressure and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113615836A true CN113615836A (en) | 2021-11-09 |
Family
ID=78378366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110705572.XA Pending CN113615836A (en) | 2021-06-24 | 2021-06-24 | Cathay hickory oil composition with function of reducing blood pressure and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113615836A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102318829A (en) * | 2011-08-17 | 2012-01-18 | 中国林业科学研究院亚热带林业研究所 | Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof |
| CN103392834A (en) * | 2013-08-14 | 2013-11-20 | 山东三星玉米产业科技有限公司 | Nutrition blend oil applicable to middle aged and elderly people and preparation method thereof |
| CN103845396A (en) * | 2014-03-05 | 2014-06-11 | 浙江大学 | Hickory sterol extractive and preparation method and application thereof |
| CN105176666A (en) * | 2015-10-13 | 2015-12-23 | 汉中福来特野生核桃油有限公司 | Production process of wild pecan oil |
-
2021
- 2021-06-24 CN CN202110705572.XA patent/CN113615836A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102318829A (en) * | 2011-08-17 | 2012-01-18 | 中国林业科学研究院亚热带林业研究所 | Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof |
| CN103392834A (en) * | 2013-08-14 | 2013-11-20 | 山东三星玉米产业科技有限公司 | Nutrition blend oil applicable to middle aged and elderly people and preparation method thereof |
| CN103845396A (en) * | 2014-03-05 | 2014-06-11 | 浙江大学 | Hickory sterol extractive and preparation method and application thereof |
| CN105176666A (en) * | 2015-10-13 | 2015-12-23 | 汉中福来特野生核桃油有限公司 | Production process of wild pecan oil |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100645385B1 (en) | Composition for anti-obesity | |
| US10624942B2 (en) | Composition for amelioration of peri- and post-menopausal symptoms and a process for producing the same | |
| KR101855821B1 (en) | Composition for relieving of menopausal symptoms and improving blood circulation | |
| CN102318829B (en) | Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof | |
| JP2015532917A (en) | New extracts of artichoke, coffea and olive for treating metabolic syndrome | |
| CN102511814A (en) | Composition with lipase inhibiting effect and application of same | |
| CN115317574A (en) | Composition for treating hyperuricemia and application thereof | |
| JP4499209B2 (en) | Obesity prevention and improvement agent | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| CN102283913A (en) | Radix aconiti carmichaeli extract and application thereof | |
| CN103690819A (en) | Traditional Chinese medicinal composition capable of preventing and treating cardiovascular and cerebrovascular diseases and with weight reducing function | |
| CN113615836A (en) | Cathay hickory oil composition with function of reducing blood pressure and preparation method thereof | |
| KR20120022085A (en) | Formulations for prevention or treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts of glycine max leaves as an active ingredient | |
| KR100419121B1 (en) | A functional food Containing herbes composition for female menopausal disorder | |
| JP2009203209A (en) | Composition for blood sugar reduction and/or anti-obesity containing material originated from bark of acacia | |
| CN108420890A (en) | A kind of composition and preparation method thereof with effect for reducing blood fat | |
| KR101420270B1 (en) | Composition comprising reacted mixture of red ginseng extract and persimmon vinegar for preventing or treating benign prostatic hyperplasia | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| KR101781432B1 (en) | The composition for assisting of hyperlipidemia using medicinal plants and Gyeongokgo thereby | |
| KR101811210B1 (en) | Composition for treatment, improvement or prevention of Diabetes comprising extract of fruit of Sorbus commixta as an effective component | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN108391815A (en) | A kind of ease constipation Weight reducing compound and preparation method | |
| KR102614272B1 (en) | Method for manufacturing promoting bone density improving composition having bone regeneration induction function | |
| KR20030085250A (en) | Alcohol fermented food or pharmaceutical composition for prevention of obesity and process for preparation thereof | |
| Nesari et al. | Fenugreek (Methika): Traditional Wisdom and Research Evidences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211109 |